We provide you with 20 years of free, institutional-grade data for FRLN stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of FRLN. Explore the full financial landscape of FRLN stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about FRLN stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Freeline Therapeutics Holdings plc(NASDAQ:FRLN) 
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product cand...
Website: https://www.freeline.life/
Founded: 2015
Full Time Employees: 200
CEO: Anne Prener
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends